Envisioning a Transformed Clinical Trials Enterprise in the United States
National Academies Press (Verlag)
978-0-309-25315-4 (ISBN)
With the need for transforming the CTE in the U.S. becoming more pressing, the IOM Forum on Drug Discovery, Development, and Translation held a two-day workshop in November 2011, bringing together leaders in research and health care. The workshop focused on how to transform the CTE and discussed a vision to make the enterprise more efficient, effective, and fully integrated into the health care system. Key issue areas addressed at the workshop included: the development of a robust clinical trials workforce, the alignment of cultural and financial incentives for clinical trials, and the creation of a sustainable infrastructure to support a transformed CTE. This document summarizes the workshop.
Table of Contents
Front Matter
1 Introduction
2 Integrating Community Practice and Clinical Trials
3 Improving Public Participation in Clinical Trials
4 Creating a New Business Model for Clinical Trials
5 Building an Infrastructure to Support Clinical Trials
6 Suggesting an Agenda for Transforming Elements of the Clinical Trials Enterprise
References
Appendix A: Workshop Agenda
Appendix B: Participant Biographies
Appendix C: Registered Workshop Attendees
Appendix D: Discussion Paper: The Clinical Trials Enterprise in the United States: A Call for Disruptive Innovation
Appendix E: Discussion Paper: Developing a Robust Clinical Trials Workforce
Appendix F: Discussion Paper: Transforming the Economics of Clinical Trials
Appendix G: Discussion Paper: Developing a Clinical Trials Infrastructure
Appendix H: Discussion Paper: Canadian Strategy on Patient-Oriented Research
Appendix I: Discussion Paper: Health Research as a Public Good
Appendix J: Discussion Paper: Novel Ways to Get Good Trial Data: The UK Experience
Appendix K: IOM Staff Paper: Context and Glossary of Select Terms Associated with the Clinical Trials Enterprise
1 Front Matter; 2 1 Introduction; 3 2 Integrating Community Practice and Clinical Trials; 4 3 Improving Public Participation in Clinical Trials; 5 4 Creating a New Business Model for Clinical Trials; 6 5 Building an Infrastructure to Support Clinical Trials; 7 6 Suggesting an Agenda for Transforming Elements of the Clinical Trials Enterprise; 8 References; 9 Appendix A: Workshop Agenda; 10 Appendix B: Participant Biographies; 11 Appendix C: Registered Workshop Attendees; 12 Appendix D: Discussion Paper: The Clinical Trials Enterprise in the United States: A Call for Disruptive Innovation; 13 Appendix E: Discussion Paper: Developing a Robust Clinical Trials Workforce; 14 Appendix F: Discussion Paper: Transforming the Economics of Clinical Trials; 15 Appendix G: Discussion Paper: Developing a Clinical Trials Infrastructure; 16 Appendix H: Discussion Paper: Canadian Strategy on Patient-Oriented Research; 17 Appendix I: Discussion Paper: Health Research as a Public Good; 18 Appendix J: Discussion Paper: Novel Ways to Get Good Trial Data: The UK Experience; 19 Appendix K: IOM Staff Paper: Context and Glossary of Select Terms Associated with the Clinical Trials Enterprise
Verlagsort | Washington |
---|---|
Sprache | englisch |
Maße | 152 x 229 mm |
Themenwelt | Medizin / Pharmazie |
ISBN-10 | 0-309-25315-2 / 0309253152 |
ISBN-13 | 978-0-309-25315-4 / 9780309253154 |
Zustand | Neuware |
Haben Sie eine Frage zum Produkt? |
aus dem Bereich